EP Patent

EP4647106A1 — Intraurethral administration device and kit

Assigned to Instituto Galzu Pesquisa Ensino Ciencia E Tecnologia Aplicada · Expires 2025-11-12 · 1y expired

What this patent protects

Intraurethral administration of medications is a practice known for rapid absorption, reduced side effects and the toxicity, in addition to reduce the pharmaceutical formulations dose. Present invention aims ergonomics and comfort for using urethral device administration of liqui…

USPTO Abstract

Intraurethral administration of medications is a practice known for rapid absorption, reduced side effects and the toxicity, in addition to reduce the pharmaceutical formulations dose. Present invention aims ergonomics and comfort for using urethral device administration of liquid or gel medication directly into the man's urethral channel. More specifically, the device comprises a housing with domed shape associated to a non-standard syringe increased volumetric capacity and extended nozzle, plunger lock, cover and kit for accommodate the small intraurethral applicator. The present invention belongs to the fields of Pharmacy and Medicine and among the various applications, special emphasis is placed on erectile dysfunction, but this urethral route can also be used to variety of pharmaceutical formulations as: anti-inflammatories, antiseptics, antibiotics, anesthetics, among other applications with different color device, allowing the use both by the patient (self-administration) and by the healthcare professional.

Drugs covered by this patent

Patent Metadata

Patent number
EP4647106A1
Jurisdiction
EP
Classification
Expires
2025-11-12
Drug substance claim
No
Drug product claim
No
Assignee
Instituto Galzu Pesquisa Ensino Ciencia E Tecnologia Aplicada
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.